Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
Received 25 September 2018
Accepted for publication 8 November 2018
Published 18 December 2018 Volume 2019:13 Pages 17—23
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Claudia Taipale,1,2 Ilkka Laine,1,3 Raimo Tuuminen1,3
1Helsinki Retina Research Group, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; 2Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 3Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland
Objective: To evaluate the functional and anatomical response after the switch from bevacizumab to aflibercept in treatment-resistant wet age-related macular degeneration (wAMD) using the treat-and-extend regimen protocol.
Design: A retrospective single-center study.
Participants: The registry consisted of 576 patients with wAMD. Of these, a total of 41 eyes of 37 patients met the study inclusion criteria with a minimum of three prior bevacizumab injections and at least 1-year follow-up after the switch to aflibercept injections for the treatment of wAMD.
Methods: Central retinal thickness (CRT) and best-corrected visual acuity (BCVA) were recorded before and after bevacizumab loading phase, before the switch to aflibercept, after aflibercept loading phase, and after the last injection or at the study end point at a minimum of 1 year from the switch.
Results: At the switch to aflibercept injections, the mean CRT was 361.1±117.7 µm (mean±SD) and BCVA was 0.29±0.19 decimals. The switch to aflibercept resulted in mean CRT resolution by 59.9±80.2 µm after the loading phase and by 61.3±102.9 µm at the study end point. Anatomical response to aflibercept switch was found in 34 of 41 eyes (83%) after the loading phase, and in 32 of 41 eyes (78%) at the study end point. BCVA improvement was 0.08±0.13 decimals in 26 of 41 eyes (63%) after the loading phase, and 0.04±0.17 decimals in 17 of 41 eyes (41%) at the study end point. The mean treatment interval of aflibercept was 8.0±2.2 weeks at the study end point.
Conclusion: Regardless of impressive anatomical outcomes of aflibercept switch, functional response was modest for most of the study eyes at long term.
Keywords: aflibercept, anti-VEGF, bevacizumab, treat-and-extend regimen protocol, wet age-related macular degeneration
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]